A Dose-Escalating, Multicenter, Single Arm, Open-Label Study of XRP9881 in Combination With Capecitabine (Xeloda), in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and Taxane Therapy.

Trial Profile

A Dose-Escalating, Multicenter, Single Arm, Open-Label Study of XRP9881 in Combination With Capecitabine (Xeloda), in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and Taxane Therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2016

At a glance

  • Drugs Larotaxel (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 14 Apr 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 14 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported by clinicaltrials.gov.
    • 17 Sep 2008 Trial identifier XRP9881 changed to EudraCT2006-006474-21 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top